Review
The multiple facets of thymic stromal
lymphopoietin (TSLP) during allergic
inflammation and beyond
Florence Roan,*,†,‡,1 Bryan D. Bell,*,†,1 Thomas A. Stoklasek,*,†,1 Masayuki Kitajima,*,†,1
Hongwei Han,*,†,1 and Steven F. Ziegler*,†,2
*Immunology Program, Benaroya Research Institute, Seattle, Washington, USA; and †Department of Immunology and ‡Division
of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA
RECEIVED DECEMBER 15, 2011; REVISED FEBRUARY 24, 2012; ACCEPTED FEBRUARY 27, 2012. DOI: 10.1189/jlb.1211622
ABSTRACT
Originally shown to promote the growth and activation
of B cells, TSLP is now known to have wide-ranging impacts on hematopoietic and nonhematopoietic cell lineages, including DCs, basophils, eosinophils, mast
cells, CD4⫹, CD8⫹, and NK T cells, B cells, and epithelial
cells. Whereas the role of TSLP in the promotion of TH2
responses has been studied extensively in the context
of lung- and skin-specific allergic disorders, it is becoming increasingly clear that TSLP may impact multiple disease states within multiple organ systems, including the blockade of TH1/TH17 responses and the
promotion of cancer and autoimmunity. This review will
highlight recent advances in the understanding of TSLP
signal transduction, as well as the role of TSLP in allergy, autoimmunity, and cancer. Importantly, these insights into the multifaceted roles of TSLP could potentially allow for novel, therapeutic manipulations of these
disorders. J. Leukoc. Biol. 91: 877– 886; 2012.
Introduction
TSLP is a member of the IL-2 cytokine family and a distant
paralog of IL-7 [1]. Murine TSLP was discovered in thymic
stromal cell line supernatants that supported B cell develop-
Abbreviations: ⫺/⫺⫽knockout, ␥c⫽common ␥ receptor chain, AD⫽atopic
dermatitis, ALL⫽acute lymphoblastic leukemia, AR⫽allergic rhinitis,
B-ALL⫽B cell acute lymphoblastic leukemia, BMDC⫽bone marrow-derived DC, CHS⫽contact hypersensitivity, COPD⫽chronic obstructive pulmonary disease, CRLF2⫽cytokine receptor-like factor 2, CRTH2⫽
Chemoattractant receptor᎑homologous molecule expressed on Th2 lymphocytes, DSS⫽dextran sulfate sodium, EC⫽epicutaneous, EoE⫽
eosinophilic esophagitis, FOXP3⫽forkhead box P3, IBD⫽inflammatory
bowel disease, IEC⫽intestinal epithelial cell, LEKTI⫽lymphoepithelial Kazaltype-related inhibitor, mDC⫽myeloid DC, MS⫽multiple sclerosis, NE⫽
neutrophil elastase, Nod⫽nucleotide-binding oligomerization domain,
NS⫽Netherton’s syndrome, OX40L⫽OX40 ligand (CD134), PAR-2⫽protease-activated receptor 2, RA⫽rheumatoid arthritis, RXR⫽retinoid X receptor, SLPI⫽secretory leukocyte peptidase inhibitor, SNP⫽single nucleotide polymorphism, SPC⫽surfactant protein C, SPINK5⫽serine peptidase
inhibitor Kazal-type 5, Treg⫽regulatory T cell, TSLP⫽thymic stromal lymphopoietin, UC⫽ulcerative colitis
0741-5400/12/0091-877 © Society for Leukocyte Biology
ment [2]. Like IL-7, TSLP can stimulate thymocytes and promote B cell lymphopoiesis. Accordingly, TSLP was studied initially as a B cell growth factor [3]. A human homolog was
identified subsequently, and further characterization of the
cytokine revealed a four-helix bundle structure containing six
conserved cysteine residues and multiple potential sites for
N-linked carbohydrate addition. As discussed later, in spite of
only 43% aa identity, human and murine TSLP share a significant degree of functional homology [4 – 6]. During allergic
inflammation, the primary producers of TSLP are epithelial
cells, keratinocytes, and stromal cells, although recent data
have demonstrated that DCs and mast cells are capable of
TSLP production [7–12].
Several groups identified a receptor capable of binding
TSLP with low affinity (TSLPR subunit), which shares 24%
identity to ␥c [13]. Upon further analyses, the functional receptor (TSLPR) was shown to include the TSLPR subunit and
the IL-7R␣ chain in humans and mice [14, 15]. The functional TSLPR is expressed by a variety of hematopoietic cell
populations, such as T cells, B cells, NK cells, monocytes, basophils, eosinophils, and DCs, as well as some nonhematopoietic
cell lineages, such as epithelial cells [16, 17]. Although classified as a hematopoietin receptor based on structural homology, the TSLPR subunit contains notable differences from canonical hematopoietin receptors. The TSLPR subunit contains
the conserved box1 sequence, which regulates JAK binding in
other cytokine receptors but lacks the conserved box2 and
contains only one tyrosine residue, 4 aa from its carboxy terminus [15]. Additionally, it contains a modified WSXWS motif
and multiple potential N-linked glycosylation sites [18].
TSLP SIGNALING
As a member of the hematopoietin receptor family, it was hypothesized originally that the TSLPR would use JAKs to activate STAT proteins downstream of the TSLPR. Indeed, TSLP
1. These authors contributed equally to this work.
2. Correspondence: Benaroya Research Institute, 1201 9th Ave., Seattle, WA
98101, USA. E-mail: sziegler@benaroyaresearch.org
Volume 91, June 2012
Journal of Leukocyte Biology 877
stimulation of multiple cell lines leads to STAT-5 phosphorylation. However, initial experiments in these cell lines showed
that TSLPR signaling occurred in the absence of JAK activation, and dominant-negative forms of JAK-1 and -2 did not affect TSLP-mediated STAT-5 activation [3, 19]. Several alternatives were implicated in TSLPR signaling, such as Src kinases
and PI3K [20]. However, two recent papers have demonstrated
robust and sustained activation of JAK-1 and -2 following TSLP
signaling in primary human DCs and primary human and
mouse CD4⫹ T cells [21, 22]. Surprisingly, unlike IL-7R␣ and
␥c in IL-7 signaling, which use JAK-1 and -3, the TSLPR subunit bound and used JAK-2 in concert with IL-7R␣-associated
JAK-1. These latest findings resolve a long-standing question
about the mode of TSLP signaling and show that TSLP-induced JAK activation precedes the activation of STAT proteins.
Whereas multiple cell lineages express the functional TSLPR
and respond to TSLP in vivo, most studies about TSLP-activated signaling pathways have been done in DCs and T cells
[16]. TSLP induced STAT-5 and STAT-1 phosphorylation in
CD4⫹ T cells [3, 13, 19, 20, 22–24], while activating STAT-1,
-3, -4, -5, and -6 in human mDCs [21]. In contrast, our lab
found activation of only STAT-1, -3, and -5 following TSLP
treatment of murine BMDCs (unpublished results). These data
suggest that TSLP is capable of activating multiple STAT proteins (Fig. 1). Whether TSLP uses similar signaling pathways in
other cell lineages and how each STAT molecule contributes
have yet to be elucidated.
CELLULAR EVENTS DOWNSTREAM OF
TSLP SIGNALING
DCs
A hallmark of the action of TSLP on DCs is the up-regulation
of cell surface molecules and chemokines, such as CCL17,
which are involved in TH2 generation and attraction. In in
vitro cultures, TSLP stimulated DC up-regulation of CD40,
CD80, and CD86. However, in contrast to other stimuli, such
as dsRNA, which also up-regulate costimulatory molecules,
TSLP preferentially induced OX40L expression through activation of noncanonical NF-B signaling, which helps drive TH2
generation [21, 25, 26]. Whereas induction of CCL17 occurred through activation of STAT-6 in human DCs [21],
STAT-5, and not STAT-6, was required for TSLP-induced
CCL17 production in murine BMDCs (unpublished results).
In humans, allogeneic, TSLP-activated DCs primed naïve
CD4⫹ T cells to produce characteristic TH2 cytokines [7, 9].
In contrast, autologous, TSLP-activated DCs supported proliferation but not differentiation of naïve CD4⫹ T cells [9], and
supported the expansion and functions of CRTH2⫹ CD4⫹
TH2 memory cells [27]. TSLP-conditioned DCs also augmented IEC-mediated IgA2 class-switching through the induction of a proliferation-inducing ligand (APRIL) [28]. Finally,
some in vitro studies have suggested a role for TSLP in the
generation of tolerigenic DCs that can drive the differentiation
of Tregs [29 –31], although other studies have indicated that
TSLP may hinder the production and/or maintenance of
FOXP3⫹ Tregs in vivo in certain disease processes [32, 33].
T lymphocytes
TSLP can also act directly on T cells and in the presence
of TCR stimulation, promoted proliferation and TH2 differentiation of naïve CD4⫹ T cells through induction of IL-4 gene
transcription [34, 35]. IL-4 further up-regulated TSLPR on
CD4⫹ T cells, resulting in a positive feedback loop. Although
IL-4 maintained TSLPR expression on in vitro-differentiated
TH2 and TH17 cells, higher TSLPR levels were present on
TH2 than on TH1 and TH17 cells, which correlated with the
ability of TSLP to drive the proliferation and survival of acti-
Figure 1. TSLP-induced signaling pathways in human and mouse DCs. TSLP activates non-canonical
NF-B and multiple STAT proteins in human DCs
to induce OX40L upregulation and CCL17 production, respectively. Activation of mouse DCs by TSLP
induces only STAT-1, -3 and -5, with the latter being
responsible for CCL17 production.
878 Journal of Leukocyte Biology
Volume 91, June 2012
www.jleukbio.org
Roan et al.
vated TH2 cells [36]. Naïve mouse CD8⫹ T cells also express
TSLPR, although TSLPR expression is low to absent on naïve
human CD8⫹ T cells; however, following activation, TSLPR
expression is up-regulated on mouse and human CD8⫹ T cells
[24, 37]. In CD4⫹ and CD8⫹ T cells, TSLP stimulation upregulated the survival protein Bcl-2 in a STAT-5-dependent
manner [22, 24, 36].
B lymphocytes
The initial studies describing TSLP demonstrated that TSLP
can support B cell lymphopoiesis [2, 3]. In in vitro studies,
pro-B cells derived from fetal liver, but not BM, responded to
TSLP, although pre-B cells from both origins could proliferate
in response to TSLP [38]. The role of TSLP in normal B cell
development or during inflammatory responses remains undefined; however, as will be discussed later, it is clear that aberrant TSLP signaling can have a significant impact on B cells,
as has been demonstrated in mouse models and by the association of mutations around the TSLPR gene locus with a subtype
of B cell leukemia [39, 40].
Innate immune cells
Multiple innate immune cells express the TSLPR and respond
to TSLP. For example, TSLP can enhance cytokine production
from mast cells, NKT cells, and eosinophils [41– 43]. Recent
work has highlighted direct effects of TSLP on basophils during TH2 cytokine-associated inflammatory diseases, including
promotion of basophil hematopoiesis from the BM in an IL-3independent manner [44].
TSLP-ASSOCIATED DISEASES
The effects of TSLP on various cell types demonstrate that
TSLP can impact type 2 inflammation through myriad different pathways. In addition, numerous studies in humans and
mice now implicate TSLP in a growing number of different
disorders beyond allergic inflammation, including infection,
cancer, and autoimmunity. The following sections describe the
disorders associated with TSLP and what is known about the
mechanisms through which TSLP may act.
Skin disorders
AD is a chronic inflammatory skin disease that affects an estimated 10 –20% of infants and young children in the United
States [45]. No SNPs in or around the TSLP gene locus have yet
been associated with AD [46]. However, whereas TSLP protein
was undetectable in nonlesional skin in AD patients, TSLP was
highly expressed in acute and chronic AD lesions [7]. TSLP was
also overexpressed in the skin of individuals with NS, a severe
skin disease characterized by AD-like lesions, as well as other allergic manifestations that result from mutations in the SPINK5
gene, which encodes the serine protease inhibitor LEKTI [47].
In mice, overexpression of TSLP in the skin was sufficient to
induce a disease phenotype characterized by all of the hallmark features of AD [48]. In the steady-state, TSLP expression
in the skin appears to be negatively regulated by RXRs, as keratinocyte-specific ablation of the RXR isotypes RXR␣ and
www.jleukbio.org
TSLP in allergy, autoimmunity, and cancer
RXR resulted in up-regulation of TSLP and development of
AD-like skin inflammation [49]. RXRs heterodimerize with
many nuclear receptor partners, including the vitamin D receptor and peroxisome proliferator-activated receptors. Administration of vitamin D or its analogs up-regulated TSLP and
resulted in the development of dermatitis [50], suggesting that
vitamin D administration may result in RXR derepression and
recruitment of coactivators to promote transcription. Keratinocyte-specific deletion of total Notch signaling, which causes
severe epidermal differentiation defects, also resulted in high
systemic levels of TSLP. However, TSLP expression in this
model may be a result of responses to the resulting skin barrier defect rather than directly from the loss of keratinocytespecific Notch signaling itself, as WT and mutant keratinocytes
produced similar amounts of TSLP in in vitro cultures [51]. In
SPINK5⫺/⫺ mice, which reproduce many of the key features
of NS, the absence of LEKTI resulted in unrestrained activity
of the serine protease kallikrein 5, which directly activated
PAR-2 and induced NF-B-mediated overexpression of TSLP
without contribution of the adaptive immune system [47, 52].
Interestingly, in SPINK5⫺/⫺/PAR-2⫺/⫺ mice, TSLP expression
was greatly diminished, although inflammation still occurred
[53]. Whether the cytokine milieu differs in the absence of
TSLP remains to be determined.
TSLP may influence the initiation and progression of allergic skin inflammation, but the relative contribution to these
stages and the cellular requirements may differ depending on
the context. LC migration and activation were seen in human
AD lesions in situ [7]. Furthermore, TSLP has been shown to
increase the number and maturation status of migratory LCs
in human skin explant cultures and to condition LCs to prime
cocultured, naïve CD4⫹ T cells to adopt an inflammatory TH2
phenotype [54]. However, mouse models of AD implicate additional cell types in the initiation and promotion of AD by
TSLP. A recent study by Oh et al. [55] implicated TSLP in mediating skin fibrosis downstream of IL-13, in part, through the
stimulation of fibrocyte collagen production. In a model of
allergic skin inflammation using EC sensitization to OVA on
tape-stripped skin, TSLP acted directly on T cells during the
challenge phase to potentiate TH2 cytokine production [56].
T cells were also required for TSLP-mediated dermal inflammation induced through intradermal delivery of rTSLP protein [57]. In contrast, TSLP was involved in sensitization and
challenge phases of FITC-mediated CHS, as ear swelling was
minimal if blockade of TSLP occurred prior to sensitization
but was only modestly reduced when TSLP blockade occurred
after sensitization but prior to challenge [58, 59]. Whereas DC
migration was intact in the absence of TSLP in EC sensitization, loss of TSLP signaling in the FITC CHS model was associated with reduced migration and activation of skin-derived,
antigen-bearing DCs. In addition, TSLP-responsive CD4⫹ T
cells were not required to induce a TH2 response in the CHS
model (unpublished results). In the setting of chronic high
TSLP expression, skin inflammation also occurred in the absence of T cells [48], possibly as a result of the ongoing stimulation of innate immune cells by TSLP.
TSLP has also been implicated in the phenomenon referred
to as the atopic march, which describes the increased likeliVolume 91, June 2012
Journal of Leukocyte Biology 879
hood of individuals with AD to develop AR and asthma later
in life [60]. Several models of induced TSLP expression in
mouse keratinocytes result in subsequent allergic airway inflammation following intranasal challenge, suggesting that
TSLP may be an important factor contributing to this progression from AD to AR and asthma [61, 62]. Whereas many of
these methods used to induce TSLP expression result in artificially high systemic levels of TSLP that are not seen in AD patients, we have found that intradermal administration of TSLP
triggers progression from AD to asthma in the absence of systemic TSLP (unpublished results). These models, as well as
approaches that allow for more specific expression or deletion
of TSLP, will be helpful in identifying the cellular targets of
TSLP and the mechanisms involved in the progression from
AD to AR and asthma.
Respiratory diseases
The initial report from Soumelis et al. [7], demonstrating high
TSLP expression in AD and potentiation of inflammatory TH2
responses by TSLP, also suggested a potential role for TSLP in
allergic airway disease. This hypothesis was supported by the
demonstration that TSLP mRNA was present in human lung
fibroblasts and bronchial epithelial and smooth muscle cells
and that aberrant levels of TSLP were associated with certain
human respiratory disorders [10, 63– 69]. Lung epithelium
and submucosa samples from asthmatics and COPD patients
contained a greater number of TSLP mRNA-positive cells and
BAL samples from these patients had a higher concentration
of TSLP protein compared with healthy controls [10, 64, 66,
68]. Although the extent of TSLP expression can be variable
in asthmatic patients, it has been shown to correlate directly
with TH2 cytokine and chemokine expression and inversely
with lung function [64, 68]. Increased expression of TSLP in
the nasal epithelium has also been found in biopsies from AR
patients and was associated with TH2 cytokines and eosinophils in epithelial-associated tissue [65, 67, 69, 70]. Genetic
studies also support a critical role for TSLP in allergic airway
disease. Several SNPs at the TSLP genomic locus found across
multiple ethnic backgrounds were associated with increased
asthma susceptibility or protection [71–78]. One such SNP
present in the genomic TSLP locus creates a novel AP-1 transcription factor-binding site that could potentially lead to increased TSLP transcription [71].
A role for TSLP in human asthma has been well supported
by a variety of mouse models, such as the SPC-TSLP mouse, in
which TSLP is constitutively expressed by the lung epithelium
under control of the SPC promoter [26]. With increasing age,
these mice developed a progressive asthma-like disease characterized by lung infiltration of eosinophils and TH2 CD4⫹ T
cells, airway remodeling, and airway hyperreactivity. Disease in
these mice was largely dependent on IL-4, IL-13, CD4⫹ T cells,
and antigen [79, 80]. CD4⫹ T cells and antigen were also required in an acute asthma model, using intranasal administration of TSLP in conjunction with antigen [79, 81]. In addition
to driving allergic inflammation in the lung following direct
TSLP administration, TSLP played a crucial role in the wellestablished OVA/alum asthma model. In this model, TSLP
protein was found in the BAL and lung after intranasal OVA
880 Journal of Leukocyte Biology
Volume 91, June 2012
challenge, and disease symptoms were curtailed in the absence
of TSLPR or when TSLP activity was blocked by antibody or
rTSLPR protein [26, 82– 85]. In the OVA mouse model of AR,
blocking TSLP also inhibited disease development [86].
Most data currently point to a primary role for TSLP in the
sensitization/priming stage of allergic airway disease. TSLP,
produced by activated human-derived lung cells, stimulated
human DCs to prime CD4⫹ TH2 cell development and mast
cell production of TH2-associated cytokines [7, 42, 87]. Furthermore, multiple studies have shown that the actions of
TSLP on DCs were responsible for the disease phenotype observed in mouse models of asthma [26, 81, 83– 85]. TSLP-induced DC expression of costimulatory molecules, in particular,
OX40L, and DC production of TH2 chemokines, such as
CCL17 and CCL21, are likely the predominant mechanisms of
action [26, 81]. However, TSLP may also influence the challenge stage of allergic airway disease by supporting TH2 CD4⫹
T cell cytokine production [56, 82– 86]. TSLP may also influence the Treg compartment. Several reports have shown the
ability of TSLP to promote the development of thymic Tregs
in vitro [88]; however, in vivo, its role is unclear. In allergic
airway disease, TSLP inhibited IL-10-mediated Treg function
and the formation of inducible Tregs to exogenous antigen
[89]. Importantly, the BAL fluid from asthmatics inhibited
pulmonary Treg function in a TSLP-dependent manner [89].
Additionally, in the OVA asthma model, Nod2 and to a lesser
extent, Nod1 stimulation blocked tolerance to OVA intranasal
challenge in a TSLP- and OX40L-dependent manner [33]. In
this model, loss of TSLP signaling correlated with increased
antigen-specific FOXP3⫹ T cells following Nod2 stimulation.
A variety of stimuli, such as IL-4, IL-13, TNF-␣, IL-1, bacterial peptidoglycan, lipoteichoic acid, dsRNA, respiratory viruses, air pollutants, and allergens have been shown to induce
TSLP expression by lung-derived parenchymal cells and immune cells [7, 11, 42, 52, 63, 87, 90 –92]. In particular, stimulation of Nod1 and Nod2 in nonhematopoietic cells was a potent inducer of TH2 immunity via TSLP [93]. These stimuli
likely all drive NF-B-dependent expression of TSLP, as was
shown to occur in human lung epithelial cells [90]. Furthermore, TSLP transcription was negatively regulated by 9-cis-RA
via RXRs in lung cells [94]. Exposure to certain infectious
agents or repeated environmental irritants may prime production of TSLP, leading to TH2-mediated human disease. For
example, even in the absence of known lung disease, lung
samples from smokers contained increased TSLP levels as compared with nonsmokers [64]. In addition, lung epithelial cells
from asthmatics produced more TSLP in response to dsRNA
(viral analog) stimulation in culture [95, 96], which may explain, at least in part, why patients with asthma tend to suffer more airway dysfunction after respiratory infections compared with healthy individuals [97]. This aberrant TSLP
production in response to lung insults may thus influence
the susceptibility of certain individuals to develop allergic
respiratory diseases such as asthma, as well as the clinical
complications that arise after environmental insults to the
lungs of these individuals.
www.jleukbio.org
Roan et al.
Collectively, these data illustrate that aberrant lung expression of TSLP is associated with human allergic airway disease
and can mimic asthma-like disease in mice. According to genetic studies and in vitro analyses, lung samples from individuals with asthma or COPD produce more TSLP in response to
lung insult as compared with samples from healthy individuals.
Clinical trials targeting TSLP in these conditions are currently
underway. According to mouse asthma models, TSLP appears
to influence the sensitization stage of allergic airway responses,
but a more in-depth examination of the influence of TSLP on
the allergic effector response is required. Where and when
TSLP acts during allergic airway disease will likely explain any
trial results and dictate future therapeutic design.
Intestinal inflammation
TSLP is constitutively expressed in the mouse and human gastrointestinal tract but can be induced further by a variety of cytokines, microbes, and microbial products [28, 98 –103]. Mice carrying gene deletions specifically affecting the gut mucosa provide
additional clues into the regulation of TSLP expression within
the gut. TSLP mRNA levels were decreased significantly in mice
with intestinal epithelial-specific deletion of Dicer [104], an enzyme involved in microRNA biosynthesis, or IB kinase- [99].
Both of these knockout mice showed increased susceptibility to
infection with the mouse whipworm Trichuris muris. TSLP expression was also decreased in mice carrying a missense mutation in
the Muc2 mucin gene that resulted in an epithelial defect and
spontaneous colitis [105]. In in vitro analyses of TSLP intestinal
function, human colonic or gastric epithelial-derived TSLP has
been implicated in conditioning DCs to drive development of
inflammatory TH2 cells [106], Tregs [31], or T cell-independent
IgA2 class-switching [28]. Whereas supernatants from human and
mouse IECs can condition DCs to drive Treg differentiation, the
requirements for TSLP may differ in humans and mice, as the
presence of TSLP was required in human but not mouse IEC
supernatants to drive a tolerigenic DC phenotype [31, 107]. Additional studies are just beginning to define whether and under
what conditions TSLP may function in these pathways in vivo.
As is seen in atopic diseases of the skin and lung, aberrant expression of TSLP was also seen in allergic diseases of the gut.
Polymorphisms in TSLP and the TSLPR were associated with the
food allergy-related disorder EoE, and this association persisted
when comparing EoE patients with allergic individuals without
EoE [108, 109]. Additionally, TSLP mRNA expression was higher
in the esophagus of pediatric patients with EoE compared with
controls and was decreased in homozygotes of the protective GG
minor allele for the rs3806932 SNP. Some studies suggest, however, that TSLP not only plays an important role in the promotion of TH2 responses but is also a key player in maintaining intestinal homeostasis and modulation of TH1/TH17 inflammation. In contrast to the increased TSLP expression seen in EoE,
decreased TSLP expression was seen in noninflamed colonic tissue in Crohn’s disease and UC, the two types of IBD [31, 98, 110,
111]. However, studies of UC have indicated that in inflamed
tissue, TSLP expression is up-regulated compared with noninflamed tissue from UC patients or controls [101, 111].
Mouse models of TH2- and TH1-type inflammation also suggest important roles for TSLP in TH2-mediated immunity, main-
www.jleukbio.org
TSLP in allergy, autoimmunity, and cancer
tenance of homeostasis, and modulation of TH1/TH17 responses
within the gut. TSLP was required to induce diarrheal disease in
a mouse model of food allergy [112] and protective TH2 responses to infection with T. muris [99]. However, TSLP was not
required for oral tolerance to OVA or for anaphylaxis and IL-4,
IL-13, and IgE production following intragastric OVA/cholera
toxin sensitization and challenge [112]. Additionally, other helminths, such as Heligmosomoides polygyrus, Nippostrongylus brasiliensis,
and Schistosoma mansoni, still induced TH2 responses in
TSLPR⫺/⫺ mice, although in some cases, these responses were
modified or slightly attenuated [113, 114]. Thus, whereas TSLP
may promote TH2 responses in the gut, it is not absolutely required for TH2-type inflammation. In contrast to T. muris, H.
polygyrus and N. brasiliensis produce excretory/secretory products
that acted on DCs to decrease IL-12/23p40 production. Of note,
protective TH2 responses can be induced in T. muris infections
in the absence of TSLP following the blockade of IFN-␥ or IL-12/
23p40 [100, 113], suggesting that TSLP may play a prominent
role in attenuating TH1 and TH17 responses.
Studies using mouse models of colitis have demonstrated important effects of TSLP in modulating the disease phenotype in
intestinal inflammation, although there have been some conflicting results. In a chemical colitis model using DSS, Taylor et al.
[100] showed that mice lacking the TSLPR developed more
acute weight loss and increased colonic inflammation, which correlated with higher levels of IFN-␥ and IL-17A within the mesenteric LNs. In contrast, Reardon et al. [17] reported comparable
disease onset and severity in the DSS colitis model between mice
that lack TSLP signaling versus controls. However, whereas WT
mice recovered after DSS withdrawal, mice lacking TSLP or its
receptor had progressive disease and weight loss [17]. Reardon et
al. [17] showed that SLPI was induced in DSS colitis in WT mice
and that this induction was lost in TSLP⫺/⫺ mice. NE is a target
of SLPI and functions to degrade a number of substrates, including progranulin, a protein important in wound healing. Consistent with a role for TSLP in the inhibition of NE, TSLP⫺/⫺ mice
displayed increased NE activity after treatment with DSS, and inhibition of NE reduced mortality in TSLP⫺/⫺ mice in this colitis
model. Whereas methodological differences may account for some
of the discrepancies between these studies, a growing body of evidence demonstrates that differences in microbiota among various
facilities can have profound effects on the development and function of the intestinal, as well as systemic, immune system [115].
Thus, further exploration of how the gut microbiota affect TSLP
expression and function may be warranted.
These studies support a role for TSLP in the promotion of
TH2 responses in the gastrointestinal system but also provide important evidence that TSLP plays a key role in the maintenance
of immune homeostasis within the gut. Not only does TSLP function to attenuate TH1/TH17 responses, it also acts directly on
the intestinal epithelium to support wound healing in colitis.
Whether TSLP also contributes to wound healing and blockade
of TH1/TH17 responses at other sites remains to be determined.
Cancer
Recent reports have suggested that TSLP is also associated
with breast and pancreatic cancers, which display an increased
infiltration of TH2 cells [116 –118]. Breast and pancreatic canVolume 91, June 2012
Journal of Leukocyte Biology 881
cer cells and cancer-associated fibroblasts have been shown to
produce TSLP in response to cancer cell-derived inflammatory
cytokines and possibly other unidentified stimuli [116 –118].
Furthermore, supernatants from these cells induced DC production of the TH2-attracting chemokines CCL17 and CCL22
and up-regulation of DC costimulatory molecules CD80, CD86,
OX40L, and TSLPR in a TSLP-dependent manner. These supernatant-primed DCs were able to promote TH2 polarizition
of CD4⫹ T cells in vitro. In support of these in vitro data, activated DCs and CCL17 and CCL22 were detected in the tumor
and draining LNs but not nondraining LNs of human patients
[116]. Importantly, a decreased ratio of TH1/TH2 cells in human pancreatic cancer cases was associated with disease progression and was an independent prognostic marker of reduced survival [116]. Whereas breast cancer cells with intact
TSLP expression were able to induce tumor growth and metastasis in mice, short hairpin RNA knockdown of TSLP in these
cells resulted in clones with minimal growth or metastasis
[117]. Tumor progression and metastasis of an injected breast
cancer or melanoma cell line were also decreased in TSLPRdeficient mice compared with WT mice [117].
Previous work has shown that TH2 cytokines promote disease progression through increased survival of cancer cells, M2
macrophage differentiation, and fibrosis (collagen degradation
and synthesis) [119 –123]. Now TSLP appears to be linked to
these phenomena in some human cancers. Alternatively, TSLP
may promote tumor progression by controlling Treg migration. CCL22 production in human breast cancer is involved in
the influx of tumor Tregs that may then alter the immunoregulatory environment [124, 125]. Further investigation is
needed to identify the important sources and targets of TSLP
within the tumor environment.
In addition to the association of TSLP with certain solid tumors, the TSLPR has been shown to be overexpressed in 5–10%
of childhood B cell progenitor ALL cases and ⬃60% of ALL
cases in children with Down’s syndrome [40, 126 –128]. Approximately 15% of adult and high-risk pediatric B-ALL cases that lack
characteristic rearrangements demonstrated TSLPR overexpression [129]. In almost all cases, TSLPR overexpression was associated with intrachromosomal deletion or rearrangement of the
TSLPR/CRLF2 locus with the Ig heavy chain locus, placing
TSLPR/CRLF2 under alternate transcriptional control downstream of the P2YR8 promoter [40, 126, 129]. These mutations
were highly correlated with the presence of JAK2 mutations and
were associated with a poor prognosis [40, 126 –131]. In murine
Ba/F3 cells, expression of TSLPR and JAK2 mutant alleles promoted growth factor-independent growth [126, 129]. Mice with
systemic overexpression of TSLP may provide a model for understanding the signaling mechanisms involved. In particular, loss of
keratinocyte-specific Notch signaling resulted in high systemic
levels of TSLP, which correlated with a rapid expansion of pre-B
cells in the early postnatal period, contributing to early mortality
in these animals [51]. Interestingly, overexpression of TSLP early
in the postnatal period was sufficient to drive a B cell lymphoproliferative disorder, but administration or induction of TSLP after
Postnatal Day 14 was not. However, other studies have shown expansion of B cell compartments following TSLP expression in
adult mice [39].
882 Journal of Leukocyte Biology
Volume 91, June 2012
The association of TSLP and TSLP signaling pathways with
hematologic malignancies, as well as solid tumors, implicates
TSLP/TSLPR in numerous regulatory pathways that support
cell growth and survival in cancer. In B-ALL, activation of signaling pathways downstream of TSLP directly promotes the
growth and survival of malignant cells, whereas in breast and
pancreatic cancer, TSLP likely contributes to multiple components of the tumor environment that affect growth and metastasis, as well as immune evasion. Several reports suggest that
TSLP/TSLPR may be useful as a prognostic marker and may
present a novel target for therapeutic intervention in cancer.
Other autoimmune diseases and issues of tolerance
Mouse models with constitutive or inducible overexpression of
TSLP have demonstrated that TSLP can be associated with autoimmune phenomena. TSLP overexpression in these mice was
associated with the development of cryoglobulinemic glomerulonephritis as a result of increased production and kidney deposition of systemic polyclonal IgM and IgG via a monocyte/macrophage-dependent mechanism [39, 132, 133]. In addition, these
mice developed red blood cell-specific autoantibodies and autoimmune hemolytic anemia in a CD4⫹ T cell- and IL-4-dependent
manner [134]. Whether TSLP is involved in human mixed cryoglobulinemia or autoimmune hemolytic anemia is unknown.
As discussed earlier, TSLP expression was decreased in IBD,
a disorder that is thought to arise as a result of inappropriate
immune activation against normally harmless microflora. Additionally, loss of TSLP signaling in a mouse model of autoimmune gastritis resulted in more severe disease [135]. Although
the impact of TSLP on colitis in mice appears more complex
[17, 100], this supports a model in which loss of TSLP, which
can block TH1/TH17 responses, leads to increased inflammation. However, data from humans and mouse models suggest
that TSLP may actively promote inflammation in TH1/TH17associated autoimmune diseases, such as RA and MS. In a proteoglycan-induced arthritis mouse model of RA, TSLPR-deficient mice had reduced immunopathology associated with decreased levels of production of IL-17, IL-1, and IL-6 but
increased IFN-␥ and IL-10 [136]. Furthermore, blocking TSLP
in a collagen-induced arthritis model ameliorated disease,
while administering rTSLP protein exacerbated disease [136,
137]. Increased synovial concentrations of TSLP, as well as
TNF-␣, have also been seen in synovial fluid from RA patients
compared with samples from patients with osteoarthritis. In in
vitro studies, TSLP-primed human mDCs induced proliferation
of self-reactive CD4⫹ T cells capable of TH1 or TH2 differentiation and TSLP priming of DCs, in conjunction with TLR3
ligand, supported TH17 differentiation [9, 137, 138]. Thus,
although the role of TSLP in RA is largely undefined, these
data provide intriguing evidence of its possible involvement.
Other autoimmune diseases, specifically MS and type 1 diabetes, have been associated with SNPs in the IL-7R␣ gene locus and altered Treg numbers or function [139 –142]. Although TSLPR pairs with IL-7R␣ and TSLP can affect Treg
development, neither disease has yet been directly linked to
TSLP. However, administration of TSLP or TSLP-treated
BMDCs into nonobese diabetic mice prevented the development of diabetes in these mice [30], suggesting a possible role
www.jleukbio.org
Roan et al.
for TSLP in disease therapy. Although the mechanisms involved in protection from diabetes have not been determined,
protection was associated with an increased number of Tregs.
One final link that has been made between TSLP and immune tolerance is in maternal-fetal tolerance during pregnancy. TSLP was produced and secreted by first-semester trophoblasts, and tissue from normal pregnancies demonstrated a
TH2 bias and higher levels of TSLP expression than samples
from miscarriages [143]. Thus, whereas TSLP expression and a
TH2 bias may lead to disease progression in cancer, TSLP may
contribute to tolerance at the maternal-fetal interface.
6.
7.
8.
9.
10.
CONCLUDING REMARKS
Incredible progress has been made in understanding the cellular
changes induced by TSLP during TH2-type inflammation. Multiple cell lineages express the functional TSLPR that helps drive
the immune response. More recent data have illustrated that
TSLP is also involved in numerous disorders beyond just allergy
and may play a role in maintaining homeostasis in diseases, such
as IBD, or in disease progression in cancer and autoimmunity.
To use the knowledge gained about the biological effects of
TSLP, a better understanding of cell-specific signaling pathways
must be delineated. Of utmost importance is deciphering
whether TSLP invokes similar signaling pathways within different
cells. Knowledge of the key targets and sources of TSLP in different disease states will also be important in furthering our comprehension of the pathophysiology of TSLP-associated disorders.
Tools that can address these questions, such as approaches that
use conditional deletion of the TSLPR and cytokine, will be important in the continued investigation of the role of TSLP during
atopic and nonatopic conditions.
ACKNOWLEDGMENTS
11.
12.
13.
14.
15.
16.
17.
18.
19.
Support was provided by the Crohn’s and Colitis Foundation of
America (F.R.) and NIH grants 5T32AI007411-19 (B.D.B. and
T.A.S.) and 5R01AI068731-05, 5R01AR056113-04, 5R01AR05569503, 1P01HL098067-02, 1R21HL102708-01A1, 1R01AR05905801A1, and 5R21AI087990-02 (S.F.Z.). We thank Matt Warren for
assisting in the preparation of this manuscript.
22.
REFERENCES
23.
1.
2.
3.
4.
5.
Leonard, W. J. (2002) TSLP: finally in the limelight. Nat. Immunol. 3,
605–607.
Friend, S. L., Hosier, S., Nelson, A., Foxworthe, D., Williams, D. E.,
Farr, A. (1994) A thymic stromal cell line supports in vitro development of surface IgM⫹ B cells and produces a novel growth factor affecting B and T lineage cells. Exp. Hematol. 22, 321–328.
Levin, S. D., Koelling, R. M., Friend, S. L., Isaksen, D. E., Ziegler, S. F.,
Perlmutter, R. M., Farr, A. G. (1999) Thymic stromal lymphopoietin: a
cytokine that promotes the development of IgM⫹ B cells in vitro and
signals via a novel mechanism. J. Immunol. 162, 677–683.
Reche, P. A., Soumelis, V., Gorman, D. M., Clifford, T., Liu, M., Travis, M.,
Zurawski, S. M., Johnston, J., Liu, Y. J., Spits, H., de Waal Malefyt, R., Kastelein, R. A., Bazan, J. F. (2001) Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J. Immunol. 167, 336–343.
Sims, J. E., Williams, D. E., Morrissey, P. J., Garka, K., Foxworthe, D.,
Price, V., Friend, S. L., Farr, A., Bedell, M. A., Jenkins, N. A., Copeland, N. G., Grabstein, K., Paxton, R. J. (2000) Molecular cloning and
biological characterization of a novel murine lymphoid growth factor.
J. Exp. Med. 192, 671–680.
www.jleukbio.org
20.
21.
24.
25.
26.
27.
28.
TSLP in allergy, autoimmunity, and cancer
Miazgowicz, M. M., Headley, M. B., Larson, R. P., Ziegler, S. F. (2009)
Thymic stromal lymphopoietin and the pathophysiology of atopic disease. Expert Rev. Clin. Immunol. 5, 547–556.
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey,
B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., Smith, K., Gorman,
D., Zurawski, S., Abrams, J., Menon, S., McClanahan, T., de Waal-Malefyt, R., Bazan, F., Kastelein, R. A., Liu, Y. J. (2002) Human epithelial
cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3, 673–680.
Erickson, M., Morkowski, S., Lehar, S., Gillard, G., Beers, C., Dooley, J.,
Rubin, J. S., Rudensky, A., Farr, A. G. (2002) Regulation of thymic epithelium by keratinocyte growth factor. Blood 100, 3269 –3278.
Watanabe, N., Hanabuchi, S., Soumelis, V., Yuan, W., Ho, S., de Waal,
M. R., Liu, Y. J. (2004) Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4⫹ T cell homeostatic expansion.
Nat. Immunol. 5, 426 –434.
Ying, S., O’Connor, B., Ratoff, J., Meng, Q., Mallett, K., Cousins, D.,
Robinson, D., Zhang, G., Zhao, J., Lee, T. H., Corrigan, C. (2005) Thymic stromal lymphopoietin expression is increased in asthmatic airways
and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 174, 8183–8190.
Kashyap, M., Rochman, Y., Spolski, R., Samsel, L., Leonard, W. J.
(2011) Thymic stromal lymphopoietin is produced by dendritic cells. J.
Immunol. 187, 1207–1211.
Moon, P. D., Choi, I. H., Kim, H. M. (2011) Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and
caspase-1 signal cascade in mast cells. Eur. J. Pharmacol. 671, 128–132.
Pandey, A., Ozaki, K., Baumann, H., Levin, S. D., Puel, A., Farr, A. G.,
Ziegler, S. F., Leonard, W. J., Lodish, H. F. (2000) Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin.
Nat. Immunol. 1, 59 –64.
Quentmeier, H., Drexler, H. G., Fleckenstein, D., Zaborski, M., Armstrong, A., Sims, J. E., Lyman, S. D. (2001) Cloning of human thymic
stromal lymphopoietin (TSLP) and signaling mechanisms leading to
proliferation. Leukemia 15, 1286 –1292.
Park, L. S., Martin, U., Garka, K., Gliniak, B., Di Santo, J. P., Muller,
W., Largaespada, D. A., Copeland, N. G., Jenkins, N. A., Farr, A. G.,
Ziegler, S. F., Morrissey, P. J., Paxton, R., Sims, J. E. (2000) Cloning of
the murine thymic stromal lymphopoietin (TSLP) receptor: formation
of a functional heteromeric complex requires interleukin 7 receptor. J.
Exp. Med. 192, 659 –670.
Ziegler, S. F., Artis, D. (2010) Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11, 289 –293.
Reardon, C., Lechmann, M., Brustle, A., Gareau, M. G., Shuman, N.,
Philpott, D., Ziegler, S. F., Mak, T. W. (2011) Thymic stromal lymphopoetin-induced expression of the endogenous inhibitory enzyme SLPI
mediates recovery from colonic inflammation. Immunity 35, 223–235.
Tonozuka, Y., Fujio, K., Sugiyama, T., Nosaka, T., Hirai, M., Kitamura,
T. (2001) Molecular cloning of a human novel type I cytokine receptor
related to delta1/TSLPR. Cytogenet. Cell Genet. 93, 23–25.
Isaksen, D. E., Baumann, H., Trobridge, P. A., Farr, A. G., Levin, S. D.,
Ziegler, S. F. (1999) Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction. J. Immunol. 163, 5971–5977.
Isaksen, D. E., Baumann, H., Zhou, B., Nivollet, S., Farr, A. G., Levin,
S. D., Ziegler, S. F. (2002) Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction.
J. Immunol. 168, 3288 –3294.
Arima, K., Watanabe, N., Hanabuchi, S., Chang, M., Sun, S. C., Liu,
Y. J. (2010) Distinct signal codes generate dendritic cell functional
plasticity. Sci. Signal. 3, ra4.
Rochman, Y., Kashyap, M., Robinson, G. W., Sakamoto, K., Gomez-Rodriguez, J., Wagner, K. U., Leonard, W. J. (2010) Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and
JAK2 reveals a key difference from IL-7-induced signaling. Proc. Natl.
Acad. Sci. USA 107, 19455–19460.
Lu, N., Wang, Y. H., Wang, Y. H., Arima, K., Hanabuchi, S., Liu, Y. J.
(2009) TSLP and IL-7 use two different mechanisms to regulate human CD4⫹ T cell homeostasis. J. Exp. Med. 206, 2111–2119.
Rochman, Y., Leonard, W. J. (2008) The role of thymic stromal lymphopoietin in CD8⫹ T cell homeostasis. J. Immunol. 181, 7699 –7705.
Ito, T., Wang, Y. H., Duramad, O., Hori, T., Delespesse, G. J., Watanabe, N., Qin, F. X., Yao, Z., Cao, W., Liu, Y. J. (2005) TSLP-activated
dendritic cells induce an inflammatory T helper type 2 cell response
through OX40 ligand. J. Exp. Med. 202, 1213–1223.
Zhou, B., Comeau, M. R., De, S. T., Liggitt, H. D., Dahl, M. E., Lewis,
D. B., Gyarmati, D., Aye, T., Campbell, D. J., Ziegler, S. F. (2005) Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6, 1047–1053.
Wang, Y. H., Ito, T., Wang, Y. H., Homey, B., Watanabe, N., Martin, R.,
Barnes, C. J., McIntyre, B. W., Gilliet, M., Kumar, R., Yao, Z., Liu, Y. J.
(2006) Maintenance and polarization of human TH2 central memory
T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 24, 827–838.
He, B., Xu, W., Santini, P. A., Polydorides, A. D., Chiu, A., Estrella, J.,
Shan, M., Chadburn, A., Villanacci, V., Plebani, A., Knowles, D. M.,
Volume 91, June 2012
Journal of Leukocyte Biology 883
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
Rescigno, M., Cerutti, A. (2007) Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelialcell secretion of the cytokine APRIL. Immunity 26, 812–826.
Watanabe, N., Wang, Y. H., Lee, H. K., Ito, T., Wang, Y. H., Cao, W.,
Liu, Y. J. (2005) Hassall’s corpuscles instruct dendritic cells to induce
CD4⫹CD25⫹ regulatory T cells in human thymus. Nature 436, 1181–
1185.
Besin, G., Gaudreau, S., Menard, M., Guindi, C., Dupuis, G. and Amrani, A. (2008) Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes 57,
2107–2117.
Iliev, I. D., Spadoni, I., Mileti, E., Matteoli, G., Sonzogni, A., Sampietro,
G. M., Foschi, D., Caprioli, F., Viale, G., Rescigno, M. (2009) Human
intestinal epithelial cells promote the differentiation of tolerogenic
dendritic cells. Gut 58, 1481–1489.
Lei, L., Zhang, Y., Yao, W., Kaplan, M. H., Zhou, B. (2011) Thymic
stromal lymphopoietin interferes with airway tolerance by suppressing
the generation of antigen-specific regulatory T cells. J. Immunol. 186,
2254 –2261.
Duan, W., Mehta, A. K., Magalhaes, J. G., Ziegler, S. F., Dong, C., Philpott, D. J., Croft, M. (2010) Innate signals from Nod2 block respiratory
tolerance and program T(H)2-driven allergic inflammation. J. Allergy
Clin. Immunol. 126, 1284 –1293.
Omori, M., Ziegler, S. (2007) Induction of IL-4 expression in CD4(⫹)
T cells by thymic stromal lymphopoietin. J. Immunol. 178, 1396 –1404.
Rochman, I., Watanabe, N., Arima, K., Liu, Y. J., Leonard, W. J. (2007)
Cutting edge: direct action of thymic stromal lymphopoietin on activated human CD4⫹ T cells. J. Immunol. 178, 6720 –6724.
Kitajima, M., Lee, H. C., Nakayama, T., Ziegler, S. F. (2011) TSLP enhances the function of helper type 2 cells. Eur. J. Immunol. 41, 1862–
1871.
Akamatsu, T., Watanabe, N., Kido, M., Saga, K., Tanaka, J., Kuzushima,
K., Nishio, A., Chiba, T. (2008) Human TSLP directly enhances expansion of CD8⫹ T cells. Clin. Exp. Immunol. 154, 98 –106.
Vosshenrich, C. A., Cumano, A., Muller, W., Di Santo, J. P., Vieira, P.
(2003) Thymic stromal-derived lymphopoietin distinguishes fetal from
adult B cell development. Nat. Immunol. 4, 773–779.
Astrakhan, A., Omori, M., Nguyen, T., Becker-Herman, S., Iseki, M.,
Aye, T., Hudkins, K., Dooley, J., Farr, A., Alpers, C. E., Ziegler, S. F.,
Rawlings, D. J. (2007) Local increase in thymic stromal lymphopoietin
induces systemic alterations in B cell development. Nat. Immunol. 8,
522–531.
Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M.,
Guttery, D. S., Haferlach, C., Harder, L., Heidenreich, O., Irving, J.,
Kearney, L., Nguyen-Khac, F., Machado, L., Minto, L., Majid, A., Moorman, A.V., Morrison, H., Rand, V., Strefford, J. C., Schwab, C., Tönnies, H., Dyer, M. J., Siebert, R., Harrison, C. J. (2009) Deregulated
expression of cytokine receptor gene, CRLF2, is involved in lymphoid
transformation in B-cell precursor acute lymphoblastic leukemia. Blood
114, 2688 –2698.
Nagata, Y., Kamijuku, H., Taniguchi, M., Ziegler, S., Seino, K. (2007)
Differential role of thymic stromal lymphopoietin in the induction of
airway hyperreactivity and Th2 immune response in antigen-induced
asthma with respect to natural killer T cell function. Int. Arch. Allergy
Immunol. 144, 305–314.
Allakhverdi, Z., Comeau, M. R., Jessup, H. K., Yoon, B. R., Brewer, A.,
Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., Delespesse, G.
(2007) Thymic stromal lymphopoietin is released by human epithelial
cells in response to microbes, trauma, or inflammation and potently
activates mast cells. J. Exp. Med. 204, 253–258.
Wong, C. K., Hu, S., Cheung, P. F., Lam, C. W. (2010) Thymic stromal
lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am. J. Respir. Cell Mol. Biol.
43, 305–315.
Siracusa, M. C., Saenz, S. A., Hill, D. A., Kim, B. S., Headley, M. B.,
Doering, T. A., Wherry, E. J., Jessup, H. K., Siegel, L. A., Kambayashi,
T., Dudek, E. C., Kubo, M., Cianferoni, A., Spergel, J. M., Ziegler, S. F.,
Comeau, M. R., Artis, D. (2011) TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 477,
229 –233.
Leung, D. Y., Nicklas, R. A., Li, J. T., Bernstein, I. L., Blessing-Moore,
J., Boguniewicz, M., Chapman, J. A., Khan, D. A., Lang, D., Lee, R. E.,
Portnoy, J. M., Schuller, D. E., Spector, S. L., Tilles, S. A. (2004) Disease management of atopic dermatitis: an updated practice parameter.
Joint Task Force on Practice Parameters. Ann. Allergy Asthma Immunol.
93, S1–S21.
Boguniewicz, M., Leung, D. Y. (2011) Atopic dermatitis: a disease of
altered skin barrier and immune dysregulation. Immunol. Rev. 242,
233–246.
Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C.,
Dubus, P., Hovnanian, A. (2009) Kallikrein 5 induces atopic dermatitislike lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206, 1135–1147.
884 Journal of Leukocyte Biology
Volume 91, June 2012
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Yoo, J., Omori, M., Gyarmati, D., Zhou, B., Aye, T., Brewer, A.,
Comeau, M. R., Campbell, D. J., Ziegler, S. F. (2005) Spontaneous
atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 202, 541–549.
Li, M., Messaddeq, N., Teletin, M., Pasquali, J. L., Metzger, D., Chambon, P. (2005) Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc. Natl. Acad. Sci. USA 102, 14795–14800.
Li, M., Hener, P., Zhang, Z., Kato, S., Metzger, D., Chambon, P. (2006)
Topical vitamin D3 and low-calcemic analogs induce thymic stromal
lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.
Proc. Natl. Acad. Sci. USA 103, 11736 –11741.
Demehri, S., Liu, Z., Lee, J., Lin, M. H., Crosby, S. D., Roberts, C. J.,
Grigsby, P. W., Miner, J. H., Farr, A. G., Kopan, R. (2008) Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by
secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 6, e123.
Kouzaki, H., O’Grady, S. M., Lawrence, C. B., Kita, H. (2009) Proteases
induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J. Immunol. 183, 1427–
1434.
Briot, A., Lacroix, M., Robin, A., Steinhoff, M., Deraison, C., Hovnanian, A. (2010) Par2 inactivation inhibits early production of TSLP,
but not cutaneous inflammation, in Netherton syndrome adult mouse
model. J. Invest. Dermatol. 130, 2736 –2742.
Ebner, S., Nguyen, V. A., Forstner, M., Wang, Y. H., Wolfram, D., Liu,
Y. J., Romani, N. (2007) Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J. Allergy Clin. Immunol. 119, 982–990.
Oh, M. H., Oh, S. Y., Yu, J., Myers, A. C., Leonard, W. J., Liu, Y. J.,
Zhu, Z., Zheng, T. (2011) IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J. Immunol. 186, 7232–7242.
He, R., Oyoshi, M. K., Garibyan, L., Kumar, L., Ziegler, S. F., Geha,
R. S. (2008) TSLP acts on infiltrating effector T cells to drive allergic
skin inflammation. Proc. Natl. Acad. Sci. USA 105, 11875–11880.
Jessup, H. K., Brewer, A. W., Omori, M., Rickel, E. A., Budelsky, A. L.,
Yoon, B. R., Ziegler, S. F., Comeau, M. R. (2008) Intradermal administration of thymic stromal lymphopoietin induces a T cell- and eosinophil-dependent systemic Th2 inflammatory response. J. Immunol. 181,
4311–4319.
Larson, R. P., Zimmerli, S. C., Comeau, M. R., Itano, A., Omori, M.,
Iseki, M., Hauser, C., Ziegler, S. F. (2010) Dibutyl phthalate-induced
thymic stromal lymphopoietin is required for Th2 contact hypersensitivity responses. J. Immunol. 184, 2974 –2984.
Boehme, S. A., Franz-Bacon, K., Chen, E. P., Sasik, R., Sprague, L. J.,
Ly, T. W., Hardiman, G., Bacon, K. B. (2009) A small molecule CRTH2
antagonist inhibits FITC-induced allergic cutaneous inflammation. Int.
Immunol. 21, 81–93.
Bieber, T. (2008) Atopic dermatitis. N. Engl. J. Med. 358, 1483–1494.
Zhang, Z., Hener, P., Frossard, N., Kato, S., Metzger, D., Li, M., Chambon, P. (2009) Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc. Natl.
Acad. Sci. USA 106, 1536 –1541.
Demehri, S., Morimoto, M., Holtzman, M. J., Kopan, R. (2009) Skinderived TSLP triggers progression from epidermal-barrier defects to
asthma. PLoS Biol. 7, e1000067.
Zhang, K., Shan, L., Rahman, M. S., Unruh, H., Halayko, A. J.,
Gounni, A. S. (2007) Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in
chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol.
Physiol. 293, L375–L382.
Ying, S., O’Connor, B., Ratoff, J., Meng, Q., Fang, C., Cousins, D.,
Zhang, G., Gu, S., Gao, Z., Shamji, B., Edwards, M. J., Lee, T. H., Corrigan, C. J. (2008) Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and
chronic obstructive pulmonary disease. J. Immunol. 181, 2790 –2798.
Kamekura, R., Kojima, T., Koizumi, J., Ogasawara, N., Kurose, M., Go,
M., Harimaya, A., Murata, M., Tanaka, S., Chiba, H., Himi, T., Sawada,
N. (2009) Thymic stromal lymphopoietin enhances tight-junction barrier function of human nasal epithelial cells. Cell Tissue Res. 338, 283–
293.
Semlali, A., Jacques, E., Koussih, L., Gounni, A. S., Chakir, J. (2010)
Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J. Allergy
Clin. Immunol. 125, 844 –850.
Kimura, S., Pawankar, R., Mori, S., Nonaka, M., Masuno, S., Yagi, T.,
Okubo, K. (2011) Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol. Res. 3, 186 –193.
Shikotra, A., Choy, D. F., Ohri, C. M., Doran, E., Butler, C., Hargadon,
B., Shelley, M., Abbas, A. R., Austin, C. D., Jackman, J., Wu, L. C.,
Heaney, L. G., Arron, J. R., Bradding, P. (2012) Increased expression
of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J. Allergy Clin. Immunol. 129, 104-11.e1–104-11.e9.
Xu, G., Zhang, L., Wang, D. Y., Xu, R., Liu, Z., Han, D. M., Wang,
X. D., Zuo, K. J., Li, H. B. (2010) Opposing roles of IL-17A and IL-25
www.jleukbio.org
Roan et al.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
in the regulation of TSLP production in human nasal epithelial cells.
Allergy 65, 581–589.
Mou, Z., Xia, J., Tan, Y., Wang, X., Zhang, Y., Zhou, B., Li, H., Han, D.
(2009) Overexpression of thymic stromal lymphopoietin in allergic rhinitis. Acta Otolaryngol. 129, 297–301.
Harada, M., Hirota, T., Jodo, A. I., Doi, S., Kameda, M., Fujita, K., Miyatake, A., Enomoto, T., Noguchi, E., Yoshihara, S., Ebisawa, M., Saito,
H., Matsumoto, K., Nakamura, Y., Ziegler, S. F., Tamari, M. (2009)
Functional analysis of the thymic stromal lymphopoietin variants in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 40, 368 –374.
Hunninghake, G. M., Soto-Quiros, M. E., Avila, L., Kim, H. P., LaskySu, J., Rafaels, N., Ruczinski, I., Beaty, T. H., Mathias, R. A., Barnes,
K. C.. (2010) TSLP polymorphisms are associated with asthma in a sexspecific fashion. Allergy 65, 1566 –1575.
Bunyavanich, S., Melen, E., Wilk, J. B., Granada, M., Soto-Quiros,
M. E., Avila, L., Lasky-Su, J., Hunninghake, G. M., Wickman, M., Pershagen, G., O’Connor, G. T., Weiss, S. T., Celedón, J. C. (2011) Thymic stromal lymphopoietin (TSLP) is associated with allergic rhinitis in
children with asthma. Clin. Mol. Allergy 9, 1.
Harada, M., Hirota, T., Jodo, A. I., Hitomi, Y., Sakashita, M., Tsunoda,
T., Miyagawa, T., Doi, S., Kameda, M., Fujita, K.. (2011) Thymic stromal lymphopoietin gene promoter polymorphisms are associated with
susceptibility to bronchial asthma. Am. J. Respir. Cell Mol. Biol. 44, 787–
793.
Hirota, T., Takahashi, A., Kubo, M., Tsunoda, T., Tomita, K., Doi, S.,
Fujita, K., Miyatake, A., Enomoto, T., Miyagawa, T.. (2011) Genomewide association study identifies three new susceptibility loci for adult
asthma in the Japanese population. Nat. Genet. 43, 893–896.
Liu, M., Rogers, L., Cheng, Q., Shao, Y., Fernandez-Beros, M. E.,
Hirschhorn, J. N., Lyon, H. N., Gajdos, Z. K., Vedantam, S., Gregersen,
P.. (2011) Genetic variants of TSLP and asthma in an admixed urban
population. PLoS One. 6, e25099.
Torgerson, D. G., Ampleford, E. J., Chiu, G. Y., Gauderman, W. J.,
Gignoux, C. R., Graves, P. E., Himes, B. E., Levin, A. M., Mathias,
R. A., Hancock, D. B.. (2011) Meta-analysis of genome-wide association
studies of asthma in ethnically diverse North American populations.
Nat. Genet. 43, 887–892.
Shamim, Z., Muller, K., Svejgaard, A., Poulsen, L. K., Bodtger, U., Ryder, L. P. (2007) Association between genetic polymorphisms in the
human interleukin-7 receptor ␣-chain and inhalation allergy. Int. J. Immunogenet. 34, 149 –151.
Headley, M. B., Zhou, B., Shih, W. X., Aye, T., Comeau, M. R., Ziegler,
S. F. (2009) TSLP conditions the lung immune environment for the
generation of pathogenic innate and antigen-specific adaptive immune
responses. J. Immunol. 182, 1641–1647.
Zhou, B., Headley, M. B., Aye, T., Tocker, J., Comeau, M. R., Ziegler,
S. F. (2008) Reversal of thymic stromal lymphopoietin-induced airway
inflammation through inhibition of Th2 responses. J. Immunol. 181,
6557–6562.
Seshasayee, D., Lee, W. P., Zhou, M., Shu, J., Suto, E., Zhang, J., Diehl,
L., Austin, C. D., Meng, Y. G., Tan, M., Bullens, S. L., Seeber, S., Fuentes, M. E., Labrijn, A. F., Graus, Y. M., Miller, L. A., Schelegle, E. S.,
Hyde, D. M., Wu, L. C., Hymowitz, S. G., Martin, F. (2007) In vivo
blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven
atopic inflammation. J. Clin. Invest. 117, 3868 –3878.
Al-Shami, A., Spolski, R., Kelly, J., Keane-Myers, A., Leonard, W. J.
(2005) A role for TSLP in the development of inflammation in an
asthma model. J. Exp. Med. 202, 829 –839.
Shi, L., Leu, S. W., Xu, F., Zhou, X., Yin, H., Cai, L., Zhang, L. (2008)
Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin. Immunol. 129, 202–210.
Li, Y. L., Li, H. J., Ji, F., Zhang, X., Wang, R., Hao, J. Q., Bi, W. X.,
Dong, L. (2010) Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. J. Asthma 47, 117–123.
Zhang, F., Huang, G., Hu, B., Song, Y., Shi, Y. (2011) A soluble thymic
stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin,
reduces the severity of allergic disease by regulating pulmonary dendritic cells. Clin. Exp. Immunol. 164, 256 –264.
Miyata, M., Hatsushika, K., Ando, T., Shimokawa, N., Ohnuma, Y., Katoh, R., Suto, H., Ogawa, H., Masuyama, K., Nakao, A. (2008) Mast cell
regulation of epithelial TSLP expression plays an important role in the
development of allergic rhinitis. Eur. J. Immunol. 38, 1487–1492.
Bleck, B., Tse, D. B., Curotto de Lafaille, M. A., Zhang, F., Reibman, J.
(2008) Diesel exhaust particle-exposed human bronchial epithelial
cells induce dendritic cell maturation and polarization via thymic stromal lymphopoietin. J. Clin. Immunol. 28, 147–156.
Mazzucchelli, R., Hixon, J. A., Spolski, R., Chen, X., Li, W. Q., Hall,
V. L., Willette-Brown, J., Hurwitz, A. A., Leonard, W. J., Durum, S. K.
(2008) Development of regulatory T cells requires IL-7R␣ stimulation
by IL-7 or TSLP. Blood 112, 3283–3292.
Nguyen, K. D., Vanichsarn, C., Nadeau, K. C. (2010) TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic
immunity in asthmatic airway. Allergy Asthma Clin. Immunol. 6, 4.
www.jleukbio.org
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
TSLP in allergy, autoimmunity, and cancer
Lee, H. C., Ziegler, S. F. (2007) Inducible expression of the proallergic
cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFB. Proc. Natl. Acad. Sci. USA 104, 914 –919.
Smelter, D. F., Sathish, V., Thompson, M. A., Pabelick, C. M., Vassallo,
R., Prakash, Y. S. (2010) Thymic stromal lymphopoietin in cigarette
smoke-exposed human airway smooth muscle. J. Immunol. 185, 3035–
3040.
Kato, A., Schleimer, R. P. (2007) Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr.
Opin. Immunol. 19, 711–720.
Magalhaes, J. G., Rubino, S. J., Travassos, L. H., Le, B. L., Duan, W.,
Sellge, G., Geddes, K., Reardon, C., Lechmann, M., Carneiro, L. A.,
Selvanantham, T., Fritz, J. H., Taylor, B. C., Artis, D., Mak, T. W.,
Comeau, M. R., Croft, M., Girardin, S. E., Philpott, D. J. (2011) Nucleotide oligomerization domain-containing proteins instruct T cell
helper type 2 immunity through stromal activation. Proc. Natl. Acad. Sci.
USA 108, 14896 –14901.
Lee, H. C., Headley, M. B., Iseki, M., Ikuta, K., Ziegler, S. F. (2008)
Cutting edge: inhibition of NF-B-mediated TSLP expression by retinoid X receptor. J. Immunol. 181, 5189 –5193.
Uller, L., Leino, M., Bedke, N., Sammut, D., Green, B., Lau, L., Howarth, P. H., Holgate, S. T., Davies, D. E. (2010) Double-stranded RNA
induces disproportionate expression of thymic stromal lymphopoietin
versus interferon- in bronchial epithelial cells from donors with
asthma. Thorax 65, 626 –632.
Brandelius, A., Yudina, Y., Calven, J., Bjermer, L., Andersson, M.,
Persson, C., Uller, L. (2011) dsRNA-induced expression of thymic stromal lymphopoietin (TSLP) in asthmatic epithelial cells is inhibited by
a small airway relaxant. Pulm. Pharmacol. Ther. 24, 59 –66.
Jackson, D. J., Johnston, S. L. (2010) The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 125, 1178 –1187.
Rimoldi, M., Chieppa, M., Salucci, V., Avogadri, F., Sonzogni, A.,
Sampietro, G. M., Nespoli, A., Viale, G., Allavena, P., Rescigno, M.
(2005) Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6, 507–514.
Zaph, C., Troy, A. E., Taylor, B. C., Berman-Booty, L. D., Guild, K. J.,
Du, Y., Yost, E. A., Gruber, A. D., May, M. J., Greten, F. R., Eckmann,
L., Karin, M., Artis, D. (2007) Epithelial-cell-intrinsic IKK- expression
regulates intestinal immune homeostasis. Nature 446, 552–556.
Taylor, B. C., Zaph, C., Troy, A. E., Du, Y., Guild, K. J., Comeau, M. R.,
Artis, D. (2009) TSLP regulates intestinal immunity and inflammation
in mouse models of helminth infection and colitis. J. Exp. Med. 206,
655–667.
Tanaka, J., Saga, K., Kido, M., Nishiura, H., Akamatsu, T., Chiba, T.,
Watanabe, N. (2010) Proinflammatory Th2 cytokines induce production of thymic stromal lymphopoietin in human colonic epithelial cells.
Dig. Dis. Sci. 55, 1896 –1904.
Zeuthen, L. H., Fink, L. N., Frokiaer, H. (2008) Epithelial cells prime
the immune response to an array of gut-derived commensals towards a
tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-. Immunology 123, 197–
208.
Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y., Grencis, R. K.
(2008) IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443–2449.
Biton, M., Levin, A., Slyper, M., Alkalay, I., Horwitz, E., Mor, H.,
Kredo-Russo, S., Avnit-Sagi, T., Cojocaru, G., Zreik, F., Bentwich, Z.,
Poy, M. N., Artis, D., Walker, M. D., Hornstein, E., Pikarsky, E., BenNeriah, Y. (2011) Epithelial microRNAs regulate gut mucosal immunity
via epithelium-T cell crosstalk. Nat. Immunol. 12, 239 –246.
Eri, R. D., Adams, R. J., Tran, T. V., Tong, H., Das, I., Roche, D. K.,
Oancea, I., Png, C. W., Jeffery, P. L., Radford-Smith, G. L., Cook,
M. C., Florin, T. H., McGuckin, M. A. (2011) An intestinal epithelial
defect conferring ER stress results in inflammation involving both innate and adaptive immunity. Mucosal Immunol. 4, 354 –364.
Kido, M., Tanaka, J., Aoki, N., Iwamoto, S., Nishiura, H., Chiba, T.,
Watanabe, N. (2010) Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cell-mediated inflammatory Th2 responses. Infect. Immun. 78,
108 –114.
Iliev, I. D., Mileti, E., Matteoli, G., Chieppa, M., Rescigno, M. (2009)
Intestinal epithelial cells promote colitis-protective regulatory T-cell
differentiation through dendritic cell conditioning. Mucosal Immunol. 2,
340 –350.
Rothenberg, M. E., Spergel, J. M., Sherrill, J. D., Annaiah, K., Martin,
L. J., Cianferoni, A., Gober, L., Kim, C., Glessner, J., Frackelton, E.,
Thomas, K., Blanchard, C., Liacouras, C., Verma, R., Aceves, S., Collins, M. H., Brown-Whitehorn, T., Putnam, P. E., Franciosi, J. P., Chiavacci, R. M., Grant, S. F., Abonia, J. P., Sleiman, P. M., Hakonarson, H.
(2010) Common variants at 5q22 associate with pediatric eosinophilic
esophagitis. Nat. Genet. 42, 289 –291.
Sherrill, J. D., Gao, P. S., Stucke, E. M., Blanchard, C., Collins, M. H.,
Putnam, P. E., Franciosi, J. P., Kushner, J. P., Abonia, J. P., Assa’ad,
A. H., Kovacic, M. B., Biagini Myers, J. M., Bochner, B. S., He, H., Hershey, G. K., Martin, L. J., Rothenberg, M. E. (2010) Variants of thymic
Volume 91, June 2012
Journal of Leukocyte Biology 885
stromal lymphopoietin and its receptor associate with eosinophilic
esophagitis. J. Allergy Clin. Immunol. 126, 160 –165.
110. Noble, C. L., Abbas, A. R., Lees, C. W., Cornelius, J., Toy, K., Modrusan, Z., Clark, H. F., Arnott, I. D., Penman, I. D., Satsangi, J., Diehl, L.
(2010) Characterization of intestinal gene expression profiles in
Crohn’s disease by genome-wide microarray analysis. Inflamm. Bowel
Dis. 16, 1717–1728.
111. Noble, C. L., Abbas, A. R., Cornelius, J., Lees, C. W., Ho, G. T., Toy,
K., Modrusan, Z., Pal, N., Zhong, F., Chalasani, S., Clark, H., Arnott,
I. D., Penman, I. D., Satsangi, J., Diehl, L. (2008) Regional variation in
gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 57, 1398 –1405.
112. Blazquez, A. B., Mayer, L., Berin, M. C. (2010) Thymic stromal lymphopoietin is required for gastrointestinal allergy but not oral tolerance. Gastroenterology 139, 1301–1309.
113. Massacand, J. C., Stettler, R. C., Meier, R., Humphreys, N. E., Grencis,
R. K., Marsland, B. J., Harris, N. L. (2009) Helminth products bypass
the need for TSLP in Th2 immune responses by directly modulating
dendritic cell function. Proc. Natl. Acad. Sci. USA 106, 13968 –13973.
114. Ramalingam, T. R., Pesce, J. T., Mentink-Kane, M. M., Madala, S.,
Cheever, A. W., Comeau, M. R., Ziegler, S. F., Wynn, T. A. (2009) Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin. J. Immunol. 182, 6452–6459.
115. Gill, N., Finlay, B. B. (2011) The gut microbiota: challenging immunology. Nat. Rev. Immunol. 11, 636 –637.
116. De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H.,
Braga, M., Di, C., V, Doglioni, C., Protti, M. P. (2011) Intratumor T
helper type 2 cell infiltrate correlates with cancer-associated fibroblast
thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208, 469 –478.
117. Olkhanud, P. B., Rochman, Y., Bodogai, M., Malchinkhuu, E., Wejksza,
K., Xu, M., Gress, R. E., Hesdorffer, C., Leonard, W. J., Biragyn, A.
(2011) Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J. Immunol. 186, 5656 –5662.
118. Pedroza-Gonzalez, A., Xu, K., Wu, T. C., Aspord, C., Tindle, S.,
Marches, F., Gallegos, M., Burton, E. C., Savino, D., Hori, T., Tanaka,
Y., Zurawski, S., Zurawski, G., Bover, L., Liu, Y. J., Banchereau, J., Palucka, A. K. (2011) Thymic stromal lymphopoietin fosters human
breast tumor growth by promoting type 2 inflammation. J. Exp. Med.
208, 479 –490.
119. Wynn, T. A. (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm.
Nat. Rev. Immunol. 4, 583–594.
120. Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton,
E. C., Su, D., Marches, F., Banchereau, J., Palucka, A. K. (2007) Breast
cancer instructs dendritic cells to prime interleukin 13-secreting CD4⫹
T cells that facilitate tumor development. J. Exp. Med. 204, 1037–1047.
121. Mantovani, A., Romero, P., Palucka, A. K., Marincola, F. M. (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371, 771–783.
122. Joyce, J. A., Pollard, J. W. (2009) Microenvironmental regulation of
metastasis. Nat. Rev. Cancer 9, 239 –252.
123. Zhang, W. J., Li, B. H., Yang, X. Z., Li, P. D., Yuan, Q., Liu, X. H., Xu,
S. B., Zhang, Y., Yuan, J., Gerhard, G. S., Masker, K. K., Dong, C., Koltun, W. A., Chorney, M. J. (2008) IL-4-induced Stat6 activities affect
apoptosis and gene expression in breast cancer cells. Cytokine 42,
39 –47.
124. Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., GoddardLeon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., Perez,
S., Pasqual, N., Faure, C., Ray-Coquard, I., Puisieux, A., Caux, C., Blay,
J. Y., M´enétrier-Caux, C. (2009) Regulatory T cells recruited through
CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Cancer Res. 69, 2000 –2009.
125. Menetrier-Caux, C., Gobert, M., Caux, C. (2009) Differences in tumor
regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 69, 7895–7898.
126. Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A., Loudin,
M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., Mikhail, F. M., Meyer, J., Carroll, A. J., Williams, R. T.,
Cheng, J., Heerema, N. A., Basso, G., Pession, A., Pui, C. H., Raimondi,
S. C., Hunger, S. P., Downing, J. R., Carroll, W. L., Rabin, K. R. (2009)
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243–1246.
127. Ensor, H. M., Schwab, C., Russell, L. J., Richards, S. M., Morrison, H.,
Masic, D., Jones, L., Kinsey, S. E., Vora, A. J., Mitchell, C. D., Harrison,
C. J., Moorman, A. V. (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117, 2129 –
2136.
128. Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz,
M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S.,
Cari,o .G, Stanulla, M., Strehl, S., Russell, L. J., Harrison, C. J., Bornhauser, B., Yoda, A., Rechavi, G., Bercovich, D., Borkhardt, A., Kempski, H., te Kronnie, G., Bourquin, J. P., Domany, E., Izraeli, S. (2010)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous
886 Journal of Leukocyte Biology
Volume 91, June 2012
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139
140.
141.
142.
143.
disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood
115, 1006 –1017.
Yoda, A., Yoda, Y., Chiaretti, S., Bar-Natan, M., Mani, K., Rodig, S. J.,
West, N., Xiao, Y., Brown, J. R., Mitsiades, C., Sattler, M., Kutok, J. L.,
DeAngelo, D. J., Wadleigh, M., Piciocchi, A., Dal Cin, P., Bradner, J. E.,
Griffin, J. D., Anderson, K. C., Stone, R. M., Ritz, J., Foà, R., Aster,
J. C., Frank, D. A., Weinstock, D. M.. (2010) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc.
Natl. Acad. Sci. USA 107, 252–257.
Cario, G., Zimmermann, M., Romey, R., Gesk, S., Vater, I., Harbott, J.,
Schrauder, A., Moericke, A., Izraeli, S., Akasaka, T., Dyer, M. J.,
Siebert, R., Schrappe, M., Stanulla, M. (2010) Presence of the P2RY8CRLF2 rearrangement is associated with a poor prognosis in non-highrisk precursor B-cell acute lymphoblastic leukemia in children treated
according to the ALL-BFM 2000 protocol. Blood 115, 5393–5397.
Harvey, R. C., Mullighan, C. G., Chen, I. M., Wharton, W., Mikhail,
F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A.,
Carroll, W. L., Devidas, M., Bowman, W. P., Camitta, B. M., Reaman,
G. H., Hunger, S. P., Downing, J. R., Willman, C. L. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of
IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric
B-progenitor acute lymphoblastic leukemia. Blood 115, 5312–5321.
Guo, S., Wietecha, T. A., Hudkins, K. L., Kida, Y., Spencer, M. W., Pichaiwong, W., Kojima, I., Duffield, J. S., Alpers, C. E. (2011) Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int. 80,
946 –958.
Taneda, S., Segerer, S., Hudkins, K. L., Cui, Y., Wen, M., Segerer, M.,
Wener, M. H., Khairallah, C. G., Farr, A. G., Alpers, C. E. (2001) Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin
transgenic mice. Am. J. Pathol. 159, 2355–2369.
Iseki, M., Omori-Miyake, M., Xu, W., Sun, X., Takaki, S., Rawlings,
D. J., Ziegler, S. F. (2012) Thymic stromal lymphopoietin (TSLP)-induced polyclonal B-cell activation and autoimmunity are mediated by
CD4⫹ T cells and IL-4. Int. Immunol. 24, 183–195.
Nishiura, H., Kido, M., Aoki, N., Iwamoto, S., Maruoka, R., Ikeda, A.,
Chiba, T., Ziegler, S. F., Watanabe, N. (2012) Increased susceptibility
to autoimmune gastritis in thymic stromal lymphopoietin receptor-deficient mice. J. Immunol. 188, 190 –197.
Hartgring, S. A., Willis, C. R., Dean Jr., C. E., Broere, F., van Eden, W.,
Bijlsma, J. W., Lafeber, F. P., van Roon, J. A. (2011) Critical proinflammatory role of thymic stromal lymphopoietin and its receptor in experimental autoimmune arthritis. Arthritis Rheum. 63, 1878 –1887.
Koyama, K., Ozawa, T., Hatsushika, K., Ando, T., Takano, S., Wako, M.,
Suenaga, F., Ohnuma, Y., Ohba, T., Katoh, R., Sugiyama, H., Hamada,
Y., Ogawa, H., Okumura, K., Nakao, A. (2007) A possible role for
TSLP in inflammatory arthritis. Biochem. Biophys. Res. Commun. 357,
99 –104.
Tanaka, J., Watanabe, N., Kido, M., Saga, K., Akamatsu, T., Nishio, A.,
Chiba, T. (2009) Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin. Exp. Allergy 39, 89 –100.
Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop,
A., Caillier, S. J., Ban, M., Goris, A., Barcellos, L. F., Lincoln, R., McCauley, J. L., Sawcer, S. J., Compston, D. A., Dubois, B., Hauser, S. L.,
Garcia-Blanco, M. A., Pericak-Vance, M. A., Haines, J. L., Multiple Sclerosis Genetics Group (2007) Interleukin 7 receptor ␣ chain (IL7R)
shows allelic and functional association with multiple sclerosis. Nat.
Genet. 39, 1083–1091.
International Multiple Sclerosis Genetics Consortium, Hafler, D. A.,
Compston, A., Sawcer, S., Lander, E. S., Daly, M. J., De Jager, P. L., de
Bakker, P. I., Gabriel, S. B., Mirel, D. B., Ivinson, A. J., Pericak-Vance,
M. A., Gregory, S. G., Rioux, J. D., McCauley, J. L., Haines, J. L., Barcellos, L. F., Cree, B., Oksenberg, J. R., Hauser, S. L. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl.
J. Med. 357, 851–862.
Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I., Wallstrom, E.,
Khademi, M., Oturai, A., Ryder, L. P., Saarela, J., Harbo, H. F., Celius,
E. G., Salter, H., Olsson, T., Hillert, J. (2007) Variation in interleukin 7
receptor ␣ chain (IL7R) influences risk of multiple sclerosis. Nat.
Genet. 39, 1108 –1113.
Todd, J. A., Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S. F., Payne, F.. (2007) Robust
associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39, 857–864.
Guo, P. F., Du, M. R., Wu, H. X., Lin, Y., Jin, L. P., Li, D. J. (2010)
Thymic stromal lymphopoietin from trophoblasts induces dendritic
cell-mediated regulatory TH2 bias in the decidua during early gestation in humans. Blood 116, 2061–2069.
KEY WORDS:
atopic · cancer · autoimmunity · skin · lung · intestines
www.jleukbio.org